Airway infections have remained a prominent feature in persons living with cystic fibrosis (CF) despite the dramatic improvements in survival in the past decades. Antimicrobials are a cornerstone of infection management for both acute and chronic maintenance indications. Historic clinical trials of antimicrobials in CF have led to the adoption of consensus guidelines for their use in clinical care. More recently, however, there are efforts to re-think the optimal use of antimicrobials for care with the advent of novel and highly effective CF transmembrane conductance regulator modulator therapies. Encouragingly, however, drug development has remained active concurrently in this space. Our review focuses on the evidence for and perspectives regarding antimicrobial use in both acute and maintenance settings in persons with CF. The therapeutic innovations in CF and how this may affect antimicrobial approaches are also discussed.

中文翻译：

---

药物，药物，药物：囊性纤维化气道感染的当前治疗范例。

尽管过去几十年生存率有了显着提高，但气道感染仍然是囊性纤维化 (CF) 患者的一个突出特征。抗微生物药物是急性和慢性维持适应症感染管理的基石。CF 中抗菌药物的历史性临床试验已导致采用其在临床护理中使用的共识指南。然而，最近，随着新型高效 CF 跨膜电导调节剂调节剂疗法的出现，人们正在努力重新考虑抗菌药物在护理中的最佳使用。然而，令人鼓舞的是，药物开发在这一领域同时保持活跃。我们的审查侧重于在 CF 患者的急性和维持环境中使用抗菌药物的证据和观点。